The Evolution of Lenacapavir in HIV Treatment
Published: July 24th 2024 | Updated: July 25th 2024The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.
Read More
Long-Acting HIV Injectable Preferable to Daily Oral Regimen
July 24th 2023A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.
Read More
Prophylactic Statin Therapy Can Reduce Cardiovascular Events in People with HIV
July 24th 2023A new study shows the use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events. The data is being reported at the International AIDS Society Conference.
Read More
Almost Zero Risk of Sexually Transmitting HIV From People on ART with Low Levels of Virus
July 23rd 2023New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.
Read More